Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain.

Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Protter AA, Martins RN, Ehrlich ME, Yue Z, Petsko GA, Gandy S.

Mol Psychiatry. 2013 Aug;18(8):882-8. doi: 10.1038/mp.2012.115. Epub 2012 Aug 7.

2.

Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.

Bharadwaj PR, Bates KA, Porter T, Teimouri E, Perry G, Steele JW, Gandy S, Groth D, Martins RN, Verdile G.

Transl Psychiatry. 2013 Dec 3;3:e332. doi: 10.1038/tp.2013.97. Review.

3.

Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine).

Ustyugov A, Shevtsova E, Bachurin S.

Mol Neurobiol. 2015 Oct;52(2):970-8. doi: 10.1007/s12035-015-9249-4. Epub 2015 Jun 30. Review.

PMID:
26123670
4.

Neuropathology of synuclein aggregates.

Duda JE, Lee VM, Trojanowski JQ.

J Neurosci Res. 2000 Jul 15;61(2):121-7. Review.

PMID:
10878583
5.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
6.

Hsp70 molecular chaperones and Parkinson's disease.

Witt SN.

Biopolymers. 2010 Mar;93(3):218-28. doi: 10.1002/bip.21302. Review.

PMID:
19768775
7.

Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.

Sabbagh MN, Shill HA.

Curr Opin Investig Drugs. 2010 Jan;11(1):80-91. Review.

8.

[Latrepirdine: a systematic review of the preclinical studies].

Cano-Cuenca N, Solís-García del Pozo J, Jordán J.

Rev Neurol. 2015 Jan 1;60(1):35-42. Review. Spanish.

9.

Lithium and autophagy.

Motoi Y, Shimada K, Ishiguro K, Hattori N.

ACS Chem Neurosci. 2014 Jun 18;5(6):434-42. doi: 10.1021/cn500056q. Epub 2014 Apr 30. Review.

10.

Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.

Moors TE, Hoozemans JJ, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin MC, van de Berg WD.

Mol Neurodegener. 2017 Jan 25;12(1):11. doi: 10.1186/s13024-017-0154-3. Review.

11.

Protective mechanisms by cystatin C in neurodegenerative diseases.

Gauthier S, Kaur G, Mi W, Tizon B, Levy E.

Front Biosci (Schol Ed). 2011 Jan 1;3:541-54. Review.

Supplemental Content

Support Center